Description

VELTAM 0.2 MG (1X10)

Indications

VELTAM 0.2 MG is primarily indicated for the management of benign prostatic hyperplasia (BPH) in men. BPH is a condition characterized by the enlargement of the prostate gland, leading to urinary symptoms such as increased frequency, urgency, and difficulty in urination. VELTAM is used to alleviate these symptoms, improving the quality of life for patients suffering from this condition.

Mechanism of Action

The active ingredient in VELTAM 0.2 MG is Tamsulosin hydrochloride, which belongs to a class of medications known as alpha-1 adrenergic antagonists. Tamsulosin works by selectively blocking the alpha-1 receptors in the smooth muscle of the prostate and bladder neck. This action leads to relaxation of the smooth muscle, resulting in improved urinary flow and a reduction in the symptoms associated with BPH. By targeting these specific receptors, Tamsulosin minimizes potential side effects associated with non-selective alpha blockers.

Pharmacological Properties

VELTAM exhibits pharmacokinetic properties that facilitate its therapeutic effects. After oral administration, Tamsulosin is rapidly absorbed, with peak plasma concentrations typically occurring within 4 to 6 hours. The bioavailability of Tamsulosin is approximately 57%, and it is extensively metabolized in the liver, primarily via the cytochrome P450 system. The elimination half-life of Tamsulosin is about 15 hours, allowing for once-daily dosing. The drug is excreted mainly through the urine, with a small percentage eliminated in feces. VELTAM’s pharmacodynamic profile supports its efficacy in reducing urinary symptoms associated with BPH.

Contraindications

VELTAM 0.2 MG is contraindicated in patients with a known hypersensitivity to Tamsulosin or any of the excipients in the formulation. It should not be used in patients with a history of orthostatic hypotension or those who are concurrently taking strong inhibitors of CYP3A4, as these conditions may exacerbate the risk of adverse effects. Additionally, VELTAM is not recommended for use in women or children due to a lack of safety and efficacy data in these populations.

Side Effects

Like all medications, VELTAM 0.2 MG may cause side effects, although not everyone will experience them. Common side effects include dizziness, headache, fatigue, and nasal congestion. Orthostatic hypotension, characterized by a sudden drop in blood pressure upon standing, may occur, particularly during the initial stages of treatment. Rare but serious side effects can include priapism (prolonged erection), severe allergic reactions, and liver dysfunction. Patients should be advised to report any unusual symptoms to their healthcare provider promptly.

Dosage and Administration

The recommended dosage of VELTAM 0.2 MG is one capsule taken orally once daily, approximately 30 minutes after the same meal each day to enhance absorption. It is essential to swallow the capsule whole and not to crush or chew it. Dosage adjustments may be necessary for patients with renal impairment or those taking concomitant medications that affect the metabolism of Tamsulosin. Regular follow-up with a healthcare provider is advised to monitor the patient’s response to treatment and adjust the dosage as needed.

Interactions

VELTAM 0.2 MG may interact with several medications, which can affect its efficacy and safety. Notably, concomitant use with other antihypertensive agents may increase the risk of hypotension. Strong inhibitors of CYP3A4, such as ketoconazole and ritonavir, can increase Tamsulosin plasma levels, necessitating caution and potential dosage adjustments. Additionally, the use of phosphodiesterase-5 inhibitors (e.g., sildenafil) may enhance the hypotensive effects of Tamsulosin. Patients should inform their healthcare provider of all medications and supplements they are taking to avoid potential interactions.

Precautions

Before starting treatment with VELTAM 0.2 MG, patients should be evaluated for any pre-existing conditions that may affect the safety of the medication. Caution is advised in patients with a history of cardiovascular disease, as Tamsulosin may cause orthostatic hypotension. Patients should be monitored for signs of hypotension, particularly during the initial treatment phase. It is also important to assess renal function prior to initiating therapy, as dose adjustments may be necessary. Patients should be counseled on the potential for dizziness and advised to avoid activities that require alertness until they know how the medication affects them.

Clinical Studies

Clinical studies have demonstrated the efficacy of VELTAM 0.2 MG in improving urinary symptoms associated with BPH. In randomized controlled trials, patients treated with Tamsulosin showed significant improvements in the International Prostate Symptom Score (IPSS) compared to placebo. Additionally, studies have indicated that Tamsulosin effectively reduces post-void residual urine volume and increases urinary flow rate. Long-term studies suggest that Tamsulosin is well-tolerated, with a favorable safety profile over extended periods of use. These findings support the use of VELTAM as a first-line treatment option for patients with moderate to severe BPH symptoms.

Conclusion

VELTAM 0.2 MG is an effective treatment option for men suffering from benign prostatic hyperplasia. Its mechanism of action, pharmacological properties, and clinical efficacy make it a valuable addition to the therapeutic arsenal for managing urinary symptoms associated with BPH. While generally well-tolerated, it is important for patients to be aware of potential side effects and drug interactions. Regular follow-up with healthcare providers is essential to optimize treatment outcomes and ensure patient safety.